Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Pharmasyntez to establish antitumor drugs production in Moscow
The first shipments from the facility are expected in 2026.
- By Newsdesk
- Moscow
- Mar 28, 2023
Post winning the auction for the right to conclude an offset contract in Moscow for the supply of seven INNs of antitumor drugs, Pharmasyntez undertakes to invest 400 million rubles in the localization of production. The city provides it with a guaranteed purchase of products over the period of four years, in the amount of 2.4 billion rubles, said Vladimir Efimov, Moscow’s Vice-Mayor.
According to Oleg Astafurov, Pharmasyntez's Vice-President for Government Relations, this contract will expand the company's geographical presence and increase its competitiveness, in part because "we can engage the best research centres in Russia's capital for the development of new innovative medicines." Pharmasyntez now has operations in five Russian cities: Saint Petersburg, Tyumen, Irkutsk, Bratsk, and Ussuriysk.
The city has concluded six offset contracts with investors for the supply of more than 80 INNs. The total volume of investments in the creation of production facilities will amount to 12.5 billion rubles.
This is the ninth offset contract concluded in Moscow since 2016, when the mechanism was introduced. In addition to Pharmasyntez, Moscow has signed contracts for the supply of medicines with Moscow Endocrine Plant, Biocad, Velpharm-M, R-Opra, and R-Pharm.